Alzheimer's Needs Cures, Not Pyrrhic Victories

As the world's largest Alzheimer's research conference kicks off in Denmark, finding a cure is a long shot at best. Still, there are companies worth watching in this space.

Jul 20, 2014 at 3:00PM

It's a tough call for investors.

With the clinical trial failure rate for Alzheimer's drugs an astounding 99.6%,  major drugmakers have seen one promising Alzheimer's treatment after another fail. The list include Bapineuzumab (Pfizer/Johnson & Johnson), Flurizan (Myriad Genetics), and Elan's vaccine--all once seen as promising approaches to treating the disease.

Still, those who have close family members with Alzheimer's, as I do, are acutely aware of the disease's devastation. A new slate of drugs is badly needed, but it won't happen unless drugmakers keep paying the tab for research.

Right now, there is no drug which can halt or even slow the progression of any form of dementia. That's a huge tragedy because Alzheimer's (and other forms of dementia) have been accurately described as a "global disaster waiting to happen." According to the World Health Organization, there are almost 8  million new cases of dementia a year. This is a staggering growth rate, and is the same size as the populations of Switzerland and Israel.

It's hard to put a dollar figure on the value of an actual Alzheimer's cure, but the direct cost of disease in America alone is $214 billion a year , with the average annual rate for nursing home care at $83,000 annually. Deutsche Bank recently stated that a cure would be worth $20 billion,  but that seems a gross underestimate. Already, $10 billion a year is spent on Alzheimer's drugs that don't help much if at all.

Old assumptions about Alzheimer's aren't panning out
Ten years ago, there was great confidence that a cure to Alzheimer's would be found. The main target of R&D for the past decade has been the buildup of plaque (amyloid beta) often found clustered in the brains of Alzheimer's patients. While initial animal studies demonstrated a clear improvement in cognition with brain plaque clearing drugs, confirming those results on human patients has proven all but impossible.

There is now some question as to whether the plaque clusters are even to blame for the disease, making it clear how little we understand about what causes Alzheimer's to begin with.

Alzheimer's drugs in developmental stages
I'm not making any predictions, but those willing to do plenty of homework may find some interesting plays among the smaller caps in the Alzheimer's space. A small-cap that's getting lots of attention is Acadia Pharmaceuticals (NASDAQ:ACAD). Acadia's drug Pimavanserin may someday prove useful for psychosis in Alzheimer's patients, as discussed in a Motley Fool article by Todd Campbell. More recently, George Budwell pointed out heavy short interest as the drug gets closer to regulatory filing for its experimental treatment--which has a more direct application to Parkinson's. Acadia also has drugs in development for glaucoma and chronic pain.

Sangamo BioSciences' Alzheimer's drug is still in phase 2 testing, but it appears to have potential. The nerve-growth factor delivers a therapeutic protein to brain nerve cells that would otherwise be destroyed by Alzheimer's. Sangamo also has a gene therapy HIV drug in Phase II, and the company is something of a darling of biotech stock gurus such as David Sobek. There's also an independent study of a small-cap with an interesting Alzheimer's candidate in the peer-reviewed journal, Proceedings of the National Academy of Sciences.

It should be noted that these companies are high risk, and they have little to fall back on if things don't pan out.

A different line in Alzheimer's research is being followed by Valeant, which of course is not a pure play on Alzheimer's by any means. Recently, the cancer drug Bexarotene, licensed by Valeant, has shown some improvements in cognition in animal studies.

Other pharmas with Alzheimer's drugs in late-stage development include AstraZeneca and Merck. Both have oral drugs known as BACE inhibitors. ISI analyst Mark Schoenebaum believes Merck is perhaps six months ahead of AstraZeneca, but phase 3 data for either company's drugs is not likely to emerge until 2017.

A major drugmaker that has suffered multiple setbacks with Alzheimer's research is Eli Lilly (NYSE:LLY). Lilly decided to double down instead of throwing in the towel with its much-publicized experimental Alzheimer's drug. The drug, Solanezumab, failed phase 3 trials with advanced Alzheimer's patients. Instead of giving up, Lily started pursuing a large-scale phase 3 clinical trial for earlier-stage patients. Many are skeptical and consider it a desperation move by Lilly, especially since Solanezumab was originally touted as Lilly's great hope of overcoming its patent cliff.

The FDA lowers the bar
The failure rate with drugs in the dementia pipeline is so severe that the FDA  lowered the bar for approval of a drug for Alzheimer's disease. That's something of a Pyrrhic victory, but lowering the bar to regulatory approval may at least keep biopharmas in the race.

As recently as March, a new blood test was designed that can predict with some accuracy whether an individual will develop Alzheimer's within three years. Having such a test available will help researchers identify candidates for treatment earlier, when the drugs being studied may be effective. At the very least, the blood test should help to spur more research.

Let's hope it does. We need a cure. 

A chance to do well by doing good.
Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. The Motley Fool has a new free report on the dream-team responsible for this game-changing blockbuster which could hugely benefit public health. CLICK HERE NOW.

Cheryl Swanson has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers